Lipid-Based Pharmaceutical Nanocarriers for Imaging Applications - Nanotechnology for Biomedical Imaging and Diagnostics - page 75

[86] ogihara-umeda i, sasaki T, Nishigori H. Active removal of radioactivity in the blood
circulation using biotin-bearing liposomes and avidin for rapid tumour imaging. Eur J
Nucl med 1993; 20 :170-172.
[87] Jaggi m, Khar r, Chauhan u, gangal s. Liposomes as carriers of technetium-99m
glucoheptonate for liver imaging. int J pharm 1991; 69 :77-79.
[88] unger EC, Winokur T, macdougall p, rosenblum J, Clair m, gatenby r, Tilcock C. Hepatic
metastases: liposomal gd-dTpA-enhanced mr imaging. radiology 1989; 171 :81-85.
[89] Kabalka gW, Buonocore E, Hubner K, davis m, Huang L. gadolinium-labeled
liposomes containing paramagnetic amphipathic agents: targeted mri contrast agents
for the liver. magn reson med 1988; 8 :89-95.
[90] Kabalka gW, davis mA, moss TH, Buonocore E, Hubner K, Holmberg E, maruyama
K, Huang L. gadolinium-labeled liposomes containing various amphiphilic gd-dTpA
derivatives: targeted mri contrast enhancement agents for the liver. magn reson med
1991; 19 :406-415.
[91] unger C, shen dK, fritz J. status of liposomes as mr contrast agents. J magn reson
imaging 1993; 3 :195-198.
[92] Tilcock C. imaging tools: liposomal agents for nuclear medicine, computed tomography,
magnetic resonance, and ultrasound. in: philippot Jr, schuber f, editors. Liposomes as
Tools in Basic Research and industry . Boca raton: CrC press; 1995. p 225-240.
[93] okada m, isoda T, Kumano s, Kagawa Y, Araki T, onishi H, Hori m, Kim T, motokui
Y, Wada T, murakami T. serine- and mannose-modified liposomal contrast agent for
computed tomography: evaluation of the enhancement in rabbit liver VX-2 tumor
model. Contrast media mol imaging 2010; 5 :140-146.
[94] Krause W, schonborn A, rupp K. CT imaging with iopromide liposomes in a rabbit
model. J Liposome res 2011; 21 :229-236.
[95] Yuan f, Leunig m, Huang sK, Berk dA, papahadjopoulos d, Jain rK. microvascular
permeability and interstitial penetration of sterically stabilized (stealth) liposomes in a
human tumor xenograft. Cancer res 1994; 54 :3352-3356.
[96] gabizon AA. Liposome circulation time and tumor targeting: implications for cancer
therapy. Adv drug deliv rev 1995; 16 :285-294.
[97] Harrington KJ. Liposomal cancer chemotherapy: current clinical applications and
future prospects. Expert opin investig drugs 2001; 10 :1045-1061.
[98] presant CA, Blayney d, proffitt rT, Turner Af, Williams LE, Nadel Hi, Kennedy p,
Wiseman C, gala K, Crossley rJ, et al . preliminary report: imaging of Kaposi sarcoma and
lymphoma in Aids with indium-111-labelled liposomes. Lancet 1990; 335 :1307-1309.
[99] Nakamura K, Kuba A, Katayama m, Hashimoto s, Takatoku K, Wakui Y. indium-111-
labelled liposomes: quality and biodistribution in mice bearing human tumor xeno-
grafts. drug deliv 1993; 1 :69-74.
[100] Kubo A, Nakamura K, sammiya T, Katayama m, Hashimoto T, Hashimoto s, Kobayashi
H, Teramoto T. indium-111-labelled liposomes: dosimetry and tumour detection in
patients with cancer. Eur J Nucl med 1993; 20 :107-113.
[101] Elbayoumi TA, Torchilin Vp. Enhanced accumulation of long-circulating liposomes
modified with the nucleosome-specific monoclonal antibody 2C5 in various tumours in
mice: gamma-imaging studies. Eur J Nucl med mol i 2006; 33 :1196-1205.
[102] Harrington KJ, mohammadtaghi s, uster ps, glass d, peters Am, Vile rg, stewart Js.
Effective targeting of solid tumors in patients with locally advanced cancers by radiola-
beled pegylated liposomes. Clin Cancer res 2001; 7 :243-254.